Every 10-Q that Xenon Pharmaceuticals Inc (XENE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XENE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XENE filings page.
Xenon Pharmaceuticals Inc. reported second-quarter 2026 results marked by higher operating losses as it advances late-stage neurology programs. For the quarter, net loss was $110.7 million, and for the first half of 2026 net loss totaled $213.0 million, with no collaboration revenue versus $7.5 million a year earlier.
Research and development expense rose to $99.2 million in Q2 and $187.7 million for the first half, driven mainly by Phase 3 studies of azetukalner in epilepsy and mood disorders and early-stage pain programs. General and administrative expense reached $47.8 million for the half. Cash, cash equivalents and marketable securities were $1.25 billion as of June 30, 2026, bolstered by an $130.0 million ATM issuance and a $707.6 million underwritten equity and pre-funded warrant offering. Management states this liquidity is expected to fund operations for at least 12 months. The company plans to submit an NDA for azetukalner in focal onset seizures in the third quarter of 2026 and continues multiple Phase 3 and Phase 1 trials across epilepsy, depression and pain.
Xenon Pharmaceuticals reported a larger net loss as it ramps late-stage development. For the quarter ended March 31, 2026, net loss widened to $102.3 million from $65.0 million a year earlier, driven by higher research and development and general and administrative costs and no milestone revenue.
R&D spending rose to $88.5 million, mainly for Phase 3 programs of azetukalner in epilepsy and depression and early-stage pain programs. Xenon strengthened its balance sheet with $843.0 million of financing cash inflows, including an underwritten equity and pre-funded warrant offering, ending the quarter with $1.34 billion in cash, cash equivalents and marketable securities to fund ongoing clinical trials and potential commercialization.
Xenon Pharmaceuticals (XENE) reported Q3 2025 results with a net loss of $90.9 million (basic and diluted loss per share $1.15). The quarter had no collaboration revenue; year-to-date revenue was $7.5 million from a Neurocrine milestone tied to NBI-921355 entering a Phase 1 study.
Operating expenses rose as late-stage programs advanced: R&D was $77.1 million and G&A was $19.3 million in Q3. Interest income was $6.2 million. Cash, cash equivalents and marketable securities totaled $555.3 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months. Net cash used in operations for the first nine months was $197.6 million.
Pipeline updates: the Phase 3 X‑TOLE2 study in focal onset seizures completed enrollment (380 randomized) with topline data anticipated in early 2026; Phase 3 X‑TOLE3 (FOS) and X‑ACKT (PGTCS) continue. Phase 3 programs in MDD (X‑NOVA2/3) and bipolar depression (X‑CEED) are underway. Early-stage pain candidates include XEN1701 (Nav1.7) and XEN1120 (Kv7) in Phase 1.
Xenon Pharmaceuticals Inc. reported results for the quarter ended June 30, 2025. Management states it held $624.8 million of cash, cash equivalents and marketable securities and expects these resources to fund operations for at least the next 12 months. Total assets were $674.3 million and total liabilities were $40.3 million, leaving shareholders' equity of $634.0 million. The company recorded a net loss of $149.8 million for the six months ended June 30, 2025 (net loss of $84.7 million for the three months), and an accumulated deficit of $1,049.2 million.
Research and development spending rose to $136.2 million for the six months, driven by azetukalner program costs (direct costs of $74.9 million). Collaboration revenue of $7.5 million was recognized related to a Neurocrine milestone; NBI-921355 is in Phase 1. Clinically, X-TOLE2 patient recruitment is complete with topline data anticipated in early 2026, and multiple Phase 3 trials (X-TOLE3, X-ACKT, X-NOVA2/3, X-CEED) are underway or enrolling.